Open Label 1b/2a Trial of a Combination of IPH2201 and Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 29 Nov 2016
At a glance
- Drugs Monalizumab (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Innate Pharma
- 06 Oct 2015 Status changed from not yet recruiting to recruiting according to an Innate Pharma media release.
- 22 Sep 2015 Status changed from planning to not yet recruiting as per ClinicalTrials.gov record.
- 19 Feb 2015 According to Innate Pharma media release, this trial is expected to begin in 2015.